Molecular Partners appoints Martin Steegmaier as chief scientific officer

Molecular Partners (MOLN) announced the appointment of Martin Steegmaier as chief scientific officer and member of the company’s executive committee, effective October 1. Martin brings a wealth of experience in oncology drug development, having previously contributed to the advancement of several innovative cancer therapies at major biotech and pharmaceutical companies. Martin Steegmaier joins Molecular Partners from Sotio Biotech, a clinical-stage company developing immunotherapies for cancer, where he was CSO and lead the development of a broad pipeline of oncology programs.